- Split View
-
Views
-
Cite
Cite
Denise A. Caruso, Lisa M. Orme, Alana M. Neale, Fiona J. Radcliff, Gerlinda M. Amor, Wirginia Maixner, Peter Downie, Timothy E. Hassall, Mimi L.K. Tang, David M. Ashley, Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer, Neuro-Oncology, Volume 6, Issue 3, July 2004, Pages 236–246, https://doi.org/10.1215/S1152851703000668
- Share Icon Share
Abstract
We conducted a phase 1 study of 9 pediatric patients with recurrent brain tumors using monocyte-derived dendritic cells pulsed with tumor RNA to produce antitumor vaccine (DCRNA) preparations. The objectives of this study included (1) establishing safety and feasibility and (2) measuring changes in general, antigen-specific, and tumor-specific immune responses after DCRNA. Dendritic cells were derived from freshly isolated monocytes after 7 days of culture with IL-4 and granulocyte-macrophage colony-stimulating factor, pulsed with autologous tumor RNA, and then cryopreserved. Patients received at least 3 vaccines, each consisting of an intravenous and an intradermal administration at biweekly intervals. The study showed that this method for producing and administering DCRNA from a single leukapheresis product was both feasible and safe in this pediatric brain tumor population. Immune function at the time of enrollment into the study was impaired in all patients tested. While humoral responses to recall antigens (diphtheria and tetanus) were intact in all patients, cellular responses to mitogen and recall antigens were below normal. Following DCRNA vaccine, 2 of 7 patients showed stable clinical disease and 1 of 7 showed a partial response. Two of 7 patients who were tested showed a tumor-specific immune response to DCRNA. This study showed that DCRNA vaccines are both safe and feasible in children with tumors of the central nervous system with a single leukapheresis.
References
Ashley, D.M., and Bigner, D.D. (
Ashley, D.M., Faiola, B., Nair, S., Hale, L.P., Bigner, D.D., and Gilboa, E. (
Bergsagel, D.E. (
Bullard, D.E., Thomas, D.G., Darling, J.L., Wikstrand, C.J., Diengdoh, J.V., Barnard, R.O., Bodmer, J.G., and Bigner, D.D. (
Cinque, S., Willems, J., Depraetere, S., Vermeire, L., and Joniau, M. (
De Vries, I.J., Krooshoop, D.J., Scharenborg, N.M., Lesterhuis, W.J., Diepstra, J.H., Van Muijen, G.N., Strijk, S.P., Ruers, T.J., Boerman, O.C., Oyen, W.J., Adema, G.J., Punt, C.J. and Figdor, C.G. (
Dhodapkar, M.V., Krasovsky, J., Steinman, R.M., and Bhardwaj, N. (
Geiger, J.D., Hutchinson, R.J., Hohenkirk, L.F., McKenna, E.A., Yanik, G.A., Levine, J.E., Chang, A.E., Braun, T.M., and Mule, J.J. (
Heiser, A., Dahm, P., Yancey, D.R., Maurice, M.A., Boczkowski, D., Nair, S.K., Gilboa, E., and Vieweg, J. (
Hosking, C.S., and Balloch, A. (
Huettner, C., Paulus, W., and Roggendorf, W. (
Mitchell, A.E., Elder, J.E., Mackey, D.A., Waters, K.D., and Ashley, D.M. (
Murphy, J.B., and Sturm, E. (
NCI. National Cancer Institute, Cancer Therapy Evaluation Program (
Porgador, A., and Gilboa, E. (
Romani, N., Reider, D., Heuer, M., Ebner, S., Kampgen, E., Eibl, B., Niedewieser, D., and Schuler, G. (
Sampson, J.H., Crotty, L.E., Lee, S., Archer, G.E., Ashley, D.M., Wikstrand, C.J., Hale, L.P., Small, C., Dranoff, G., Friedman, A.H., Friedman, H.S., and Bigner, D.D. (
Shelton, M.S., Meek, F., and Hoskings, C.S. (
Shirai, Y. (
Simonsen, O., Bentzon, M.W., and Heron, I. (
Stockwin, L.H., McGonagle, D., Martin, I.G., and Blair, G.E. (
Tada, M., and de Tribolet, N. (
Yu, J.S., Wheeler, C.J., Zeltzer, P.M., Ying, H., Finger, D.N., Lee, P.K., Yong, W.H., Incardona, F., Thompson, R.C., Riedinger, M.S., Zhang, W., Prins, R.M., and Black, K.L. (
Author notes
Departments of Hematology and Oncology (D.A.C, L.M.O., A.M.N., F.J.R., G.M.A., P.D., D.M.A.),Neurosurgery (W.M.), andImmunology (M.L.K.T.), The Royal Children's Hospital, Parkville, Victoria, 3051;Department of Hematology and Oncology, The Royal Children's Hospital, Brisbane, Queensland, 4029 (T.E.H.);Department of Pediatrics (D.A.C., D.M.A.), The University of Melbourne, Parkville, Victoria, 3052;The Murdoch Childrens Research Institute (D.A.C., A.M.N., G.M.A., T.E.H., M.L.K.T., D.M.A.), Parkville, Victoria, 3052; Australia
- immune response
- brain tumors
- central nervous system
- granulocyte-macrophage colony-stimulating factor
- antigens
- child
- cryopreservation
- dendritic cells
- growth factor
- interleukin-4
- leukapheresis
- mitogens
- monocytes
- pediatrics
- mental recall
- safety
- vaccines
- diphtheria
- neoplasms
- tetanus
- rna
- immunologic function
- brain tumor, childhood
- young adult
- partial response
- mrna vaccines